Fecal Microbiota Transplantation: a Future Therapeutic Option for Obesity/Diabetes?

Judith Aron-Wisnewsky, Karine Clément, Max Nieuwdorp, Judith Aron-Wisnewsky, Karine Clément, Max Nieuwdorp

Abstract

Purpose of review: The aim of this review is to summarize the current data available on the metabolic effects of fecal microbiota transplantation (FMT) including obesity and glucose metabolism in humans.

Recent findings: Gut microbiota dysbiosis is a frequent characteristic observed in obesity and related metabolic diseases. Pieces of evidence mostly generated in mouse models suggest that rescuing this dysbiosis associates with improved metabolism. In humans, dietary or bariatric surgery interventions are often accompanied by complete or partial restoration of this dysbiosis together with weight reduction and metabolic amelioration. FMT is an interesting option to modify gut microbiota and has been associated with improved clinical outcomes, albeit only used in routine care for Clostridium difficile infection. However, there are only limited data on using FMT in the metabolic context. FMT from lean donors significantly improves insulin sensitivity in obese subjects with metabolic syndrome. However, there is a wide range of clinical responses. Interestingly in subjects with high microbial gene richness at baseline and when FMT donors that are metabolically compromised are used, no metabolic improvement is seen. Moreover, more studies evaluating the effect of FMT in patients with overt type 2 diabetes are warranted. Furthermore, interventions (in the receiver prior to FMT) aiming to enhance FMT response also need evaluation.

Keywords: Encapsulated feces; Fecal microbiota transplantation; Microbiota; Obesity; Type 2 diabetes.

References

    1. Proc Natl Acad Sci U S A. 2004 Nov 2;101(44):15718-23
    1. Nature. 2006 Dec 21;444(7122):1022-3
    1. Cell Host Microbe. 2008 Apr 17;3(4):213-23
    1. Gut. 2009 Aug;58(8):1091-103
    1. Am J Clin Nutr. 2011 Jul;94(1):58-65
    1. Science. 2011 Oct 7;334(6052):105-8
    1. Clin Infect Dis. 2011 Nov;53(10):994-1002
    1. Gastroenterology. 2012 Mar;142(3):490-6
    1. J Clin Gastroenterol. 2012 Feb;46(2):145-9
    1. Am J Gastroenterol. 2012 May;107(5):761-7
    1. Am J Gastroenterol. 2012 Jul;107(7):1079-87
    1. Gut Microbes. 2012 May-Jun;3(3):203-20
    1. Nature. 2012 May 09;486(7402):222-7
    1. Gastroenterology. 2012 Oct;143(4):913-6.e7
    1. Aliment Pharmacol Ther. 2012 Sep;36(6):503-16
    1. Nature. 2012 Oct 4;490(7418):55-60
    1. Gut. 2013 Aug;62(8):1112-21
    1. N Engl J Med. 2013 Jan 31;368(5):407-15
    1. Gut Microbes. 2013 Mar-Apr;4(2):125-35
    1. Am J Gastroenterol. 2013 Apr;108(4):478-98; quiz 499
    1. Am J Gastroenterol. 2013 Apr;108(4):500-8
    1. Sci Transl Med. 2013 Mar 27;5(178):178ra41
    1. Proc Natl Acad Sci U S A. 2013 May 28;110(22):9066-71
    1. Nature. 2013 Jun 6;498(7452):99-103
    1. Gut. 2014 May;63(5):727-35
    1. Curr Gastroenterol Rep. 2013 Aug;15(8):337
    1. Nature. 2013 Aug 29;500(7464):541-6
    1. Nature. 2013 Aug 29;500(7464):585-8
    1. Science. 2013 Sep 6;341(6150):1241214
    1. Gastroenterology. 2013 Nov;145(5):946-53
    1. Am J Gastroenterol. 2013 Oct;108(10):1620-30
    1. Clin Microbiol Infect. 2014 Mar;20 Suppl 2:1-26
    1. World J Gastroenterol. 2013 Nov 7;19(41):7213-6
    1. Nature. 2014 Jan 23;505(7484):559-63
    1. Clin Infect Dis. 2014 Jun;58(11):1515-22
    1. MBio. 2014 Jun 17;5(3):e00893-14
    1. J Gastroenterol Hepatol. 2015 Jan;30(1):51-8
    1. JAMA. 2014 Nov 5;312(17):1772-8
    1. PLoS One. 2014 Oct 20;9(10):e109434
    1. Aliment Pharmacol Ther. 2015 May;41(9):835-43
    1. Gastroenterology. 2015 Jul;149(1):102-109.e6
    1. Ann Intern Med. 2015 May 5;162(9):630-8
    1. World J Gastroenterol. 2015 May 7;21(17):5359-71
    1. Gastroenterology. 2015 Jul;149(1):223-37
    1. Open Forum Infect Dis. 2015 Feb 04;2(1):ofv004
    1. Gut. 2016 Mar;65(3):426-36
    1. Cell Metab. 2015 Aug 4;22(2):228-38
    1. J Crohns Colitis. 2016 Apr;10(4):387-94
    1. Nat Rev Nephrol. 2016 Mar;12(3):169-81
    1. Nature. 2015 Dec 10;528(7581):262-266
    1. JAMA. 2016 Jan 12;315(2):142-9
    1. Science. 2016 Apr 29;352(6285):586-9
    1. Nature. 2016 Jul 21;535(7612):376-81
    1. Nutr Metab (Lond). 2016 Aug 23;13(1):57
    1. EMBO Mol Med. 2017 Jan;9(1):1-3
    1. Aliment Pharmacol Ther. 2017 Jan;45(2):222-239
    1. Nat Med. 2017 Jan;23(1):107-113
    1. Gut. 2017 Apr;66(4):569-580
    1. Gastroenterology. 2017 Jul;153(1):87-97.e3
    1. J Crohns Colitis. 2017 Oct 1;11(10):1180-1199
    1. Nat Med. 2017 Jul;23(7):850-858
    1. Gut Microbes. 2017 May 4;8(3):253-267
    1. Aliment Pharmacol Ther. 2017 Sep;46(5):479-493
    1. Cell Metab. 2017 Oct 3;26(4):611-619.e6
    1. Microb Biotechnol. 2018 Jan;11(1):163-175
    1. United European Gastroenterol J. 2017 Oct;5(6):868-879
    1. Cureus. 2017 Aug 23;9(8):e1599
    1. Gut Microbes. 2018 Mar 4;9(2):155-165
    1. Oncotarget. 2017 Oct 4;8(51):88894-88903
    1. JAMA. 2017 Nov 28;318(20):1985-1993
    1. Diabetologia. 2018 Apr;61(4):810-820
    1. Clin Infect Dis. 2018 Mar 19;66(7):987-994
    1. J Am Heart Assoc. 2018 Mar 26;7(7):
    1. Obesity (Silver Spring). 2018 May;26(5):792-800
    1. Curr Diab Rep. 2018 Jun 21;18(8):55
    1. J Hosp Infect. 2018 Oct;100(2):148-151
    1. Transpl Infect Dis. 2018 Dec;20(6):e12967
    1. Psychother Psychosom. 2019;88(1):58-60
    1. Front Endocrinol (Lausanne). 2019 Jan 30;10:29
    1. Obes Sci Pract. 2018 Nov 28;5(1):68-74
    1. BMJ Open. 2019 Mar 30;9(3):e017995
    1. Semin Immunopathol. 2019 Jul;41(4):461-475
    1. Gut. 2019 May 30;:null

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi